A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma

Table 2 Adverse events

Adverse event	Worst grade (n = 13)
Adverse event	1	2	3	4	Total
Overall	1	5	6	1	13	100%
Nausea	1	6	0	0	7	54%
Musculoskeletal pain^†	2	3	0	0	5	38%
Neutrophil count decreased	0	1	2	0	3	23%
Anaemia	0	1	2	0	3	23%
Diarrhoea	2	0	1	0	3	23%
Anorexia	0	3	0	0	3	23%
Peripheral sensory neuropathy	0	3	0	0	3	23%
Dizziness	2	1	0	0	3	23%
Fatigue	3	0	0	0	3	23%
Fever	0	0	1	1	2	15%
Renal dysfunction^‡	0	0	2	0	2	15%
URTI	0	2	0	0	2	15%
Constipation	1	1	0	0	2	15%
Pruritus	2	0	0	0	2	15%
Dysgeusia	2	0	0	0	2	15%
Sore throat	2	0	0	0	2	15%

Grading (severity) of adverse events regardless of relationship to study treatment and occurring in more than 10% of subjects
LFT liver function tests, URTI upper respiratory tract infection
^†Musculoskeletal pain includes muscle or bone pain unrelated to bone marrow biopsy procedure
^‡Renal dysfunction includes increase in blood urea, creatinine, reduced estimated glomerular filtration rate and acute renal failure

ISSN: 1868-7083